SPML.BO · BSE
SPECIALITY MEDICINES LIMITED
₹150
+0.00% (₹0)
Prev. close
₹150
Volume
3,000
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SPECIALITY MEDICINES LIMITED
Speciality Medicines Limited engages in the manufacturing, marketing, and distribution of finished formulations of specialty pharmaceutical products in India and internationally. The company offers tablets, capsules, cream, syrups, eye drops, gel, infusion, inhalation, inhaler, injection, nasal spray, ointment, ophthalmic, oral solution, oral suspension, sachet, and suspension for oncology, immunology, neurology, and rare diseases therapeutic areas. It also provides patient, hospitals, institutions and NGO supplies, validated controlled supply management, the authenticity of the product by providing documents, warehousing facility, and tracking and on-time delivery services. In addition, the company engages in the contract manufacturing business. The company was incorporated in 2021 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Parthkumar Babulal Goyani
Headquarters
Mumbai
Employees
20
Website
specialitymedicine.comExchange
View on BSE ↗Key stats
Market cap
₹131.79 Cr
P/E ratio (TTM)
10.1
EPS (TTM)
₹14.90
Shares float
25.20 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹23.18 Cr | ₹27.52 Cr | ₹58.27 Cr | ₹75.29 Cr | |
| EBITDA | — | ₹3.60 Cr | ₹5.39 Cr | ₹9.26 Cr | ₹14.51 Cr |
| — | ₹1.70 Cr | ₹2.93 Cr | ₹7.20 Cr | ₹13.03 Cr | |
| Diluted EPS | ₹1.68 | ₹1.93 | ₹3.34 | ₹8.19 | ₹20.11 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹13.26 Cr | ₹22.68 Cr | ₹40.01 Cr | ₹95.22 Cr | |
| ₹3.64 Cr | ₹2.86 Cr | ₹5.05 Cr | ₹6.64 Cr | |
| Stockholders' equity | ₹5.93 Cr | ₹15.06 Cr | ₹30.62 Cr | ₹71.19 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-3.65 Cr | ₹-4.80 Cr | ₹-6.43 Cr | ₹-1.28 Cr | |
| Investing cash flow | ₹-11.80 L | ₹-2.52 L | ₹-1.43 Cr | ₹-2.83 Cr |
| ₹3.88 Cr | ₹4.81 Cr | ₹8.46 Cr | ₹27.82 Cr | |
| Capital expenditure | ₹-7.97 L | ₹-2.52 L | ₹-60.71 L | ₹-80,000 |
| End cash position | ₹26.15 L | ₹24.90 L | ₹84.58 L | ₹24.55 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| SPECIALITY MEDICINES LIMITED | ₹131.79 Cr | ₹150 | 10.1 | 1.85 | 18.3% | 0.09 | +29.2% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.